Global pharmaceutical company Almirall has collaborated with research group Nanomol, of the Institute of Material Science of Barcelona from the Spanish National Research Council (ICMAB-CSIC), and the Leitat Technology Centre of Nanomedicine to conduct a research project.
A new study published in the Journal of Allergy and Clinical Immunology (JACI) has suggested that the cause of eczema is due to a protein deficiency.
According to a new study, a combination of adapalene 0.3% and benzoyl peroxide 2.5% gel (A/BPO) has indicated to be superior to a vehicle for the treatment of severe acne.
Global pharmaceutical company Allergan and biopharmaceutical company Paratek have confirmed that two phase 3 trials of sarecycline met their 12-week primary efficacy endpoints.
A study published in the Journal of Clinical and Aesthetic Dermatology has reported positive results for the Intensif microneedling fractional radiofrequency applicator by ENDYMED for improving acne scarring and skin texture.
A study published in BioMed Central (BMC) Dermatology has suggested that the outcome from clinical treatment with adjuvant therapies, such as facial cleansing, topical treatments and moisturising, can greatly affect the improvement of mild-to-moderate acne vulgaris.
Dermatological distribution company SkinMed has introduced a training course aimed at educating practitioners about the treatment of acne and rosacea without antibiotics.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Bocouture, a botulinum neurotoxin type A treatment, in the UK for treatment of upper facial lines.
International pharmaceutical company Galderma has increased its investment in research and innovation, initiating six new Phase III and IV US aesthetic clinical trials.
A consensus committee from the National Rosacea Society (NRS) has published a new standard classification system of rosacea online in the Journal of the American Academy of Dermatology.